A breakthrough study from Mass General Brigham shows that evolocumab, a powerful cholesterol-lowering drug, can prevent first-time heart attacks and strokes in high-risk diabetes patients who don't yet have diagnosed heart disease. The PCSK9 inhibitor reduced major cardiovascular events by 31% over five years compared to placebo, while cutting LDL cholesterol levels by 51%. This challenges current treatment guidelines that typically reserve intensive cholesterol therapy only for patients who already have cardiovascular disease. The findings suggest earlier intervention with evolocumab could prevent heart disease before it develops in vulnerable populations.
